Supplemental Figure 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

FGFR3 siRNA and R3Mab diminish MMP-1 and MMP-10 mRNA leves in UMUC-14 cells.</p

Supplemental Figure 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

FGFR3 knockdown reduces MMP-1 and MMP-10 mRNA expression in RT112 cells.</p

Supplemental Figures 6 and 7 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

R3Mab reduces serum levels of human MMP-1 and pro-MMP-10 in mice bearing bladder tumor xenografts.</p

Supplemental Table 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

List of patient information in the phase I study.</p

Supplemental Figure 5 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

R3Mab attenuates xenograft growth of UMUC-14 tumors.</p

Supplemental Table 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

Contains a list of genes regulated by FGFR3 shRNA in RT112 cells.</p

Supplemental Figure 8 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

Lack of effect of R3Mab on serum pro-MMP-10 levels in mice with SW780 tumors.</p

Supplemental Figure 3 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

FGFR3 knockdown in RT112 cells reduces total MMP-10 protein level in conditioned medium.</p

Supplemental Figure 4 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

R3Mab reduces MMP protein secretion in the conditioned medium by UMUC-14 cells.</p

Additional file 1: of A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Table S1. All-grade AEs related to any study drug occurring in ≥ 15% of all patients and corresponding grade ≥ 3 AEs. Table S2. SAEs related to any study drug (regardless of causality). Table S3. AEs and grade ≥ 3 AEs of special interest (regardless of causality). Table S4. Summary of DLTs observed during the study. (DOCX 66 kb